TITLE

Feasibility, cost-effectiveness and patients’ acceptance of point-of-care INR testing in a hospital-based anticoagulation clinic

AUTHOR(S)
Ming Chai Kong; Teong Guan Lim; Heng Joo Ng; Yiong Huak Chan; Lai Heng Lee
PUB. DATE
November 2008
SOURCE
Annals of Hematology;Nov2008, Vol. 87 Issue 11, p905
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Point-of-care (POC) coagulometers are increasingly used by patients for self-monitoring of oral vitamin K antagonists therapy. We studied the feasibility of introducing POC international normalised ratio (INR) testing in place of standard laboratory assays in a hospital-based anticoagulation clinic with 250 active patients. The CoaguChek® XS system was first validated in 253 INR samples and found to have a correlation of r = 0.945 with standard assays. Variations increased with INR readings above 3.5 and this was chosen as the cutoff for acceptance of POC INR results. POC testing was done for 1,332 clinic visits during the subsequent 6-month study. Rate of rejections of INR over 3.5 was 4.3% (95% CI 3.3–5.5%). POC testing reduced clinic visit duration by 35 min ( p < 0.001, 95% CI 25–45) without cost increments to patients or the laboratory. Among 232 respondents surveyed, 87.5% (95% CI 82.5–91.5%) preferred POC INR monitoring. Rates of thrombosis and major bleeding complications were 1.2% (95% CI 0.2–3.5%) and 0.4% (95% CI 0.01–2.2%), respectively. In conclusion, provided mechanisms are in place to address increased variations of INR at higher ranges, POC testing can be successfully implemented in busy hospital-based anticoagulation clinics.
ACCESSION #
34509828

 

Related Articles

  • Anticoagulant (Major drug group).  // Royal Society of Medicine: Medicines;2002, p68 

    The article presents information on anticoagulant agents. These agents prevent the clotting of blood and help break up blood clots that have formed. Therapeutically, anticoagulants are used to prevent the formation of and to treat blood clots in conditions such as thrombosis and embolism,...

  • Independent Nurse: Clinical Top 50 - Oral anticoagulation. Provan, Drew // GP: General Practitioner;12/2/2005, p121 

    This article reports that therapeutic anticoagulation is increasing by 20 percent each year. By 1996, more than 300,000 British patients required oral anticoagulation. It is informed that warfarin is the preferred oral anticoagulant; phenindione is used in cases of warfarin allergy. Oral...

  • Lupus Anticoagulant Assays: Questions Answered and to Be Answered. Teruya, Jun; West, Aaron G.; Suell, Mary Nell // Archives of Pathology & Laboratory Medicine;Jun2007, Vol. 131 Issue 6, p885 

    Context.—Lupus anticoagulants are antibodies with heterogenous specificities to phospholipids. They have been associated with clinical syndromes consisting of thrombosis and recurrent fetal loss. Objective.—To address questions about the laboratory assay aspects of lupus...

  • PERIPHERAL ARTERIAL EMBOLISM. Haimovici, Henry // Angiology;Feb1950, Vol. 1 Issue 1, p20 

    The article cites several studies related to peripheral arterial embolism. Ever since 1911, when the first successful embolectomy was performed, there has been a steadily growing literature on peripheral arterial embolism. From then until 1934, embolectomy was considered the only weapon against...

  • Mechanical Prosthetic Heart Valve Thrombosis Despite Optimal Anticoagulation in a Patient with Congenital Thrombophilia (Factor V Leiden). Pegoraro, Cinizia; Biasiolo, Alessandra; Iliceto, Sabino; Pengo, Vittorio // Clinical & Applied Thrombosis/Hemostasis;Jan2003, Vol. 9 Issue 1, p89 

    Failure of anticoagulant therapy in a patient with a St. Jude heart valve in the mitral position is reported. After 8 years of optimal anticoagulation at an International Normalized Ratio between 2.5 and 3.5, a floating thrombus was discovered by chance during transthoracic echocardiography and...

  • Corrigendum to The role of novel anticoagulants in the management of venous thromboembolism.  // Vascular Medicine;Aug2014, Vol. 19 Issue 4, p337 

    The authors (Nedaa Skeik, Caleb J Murphy and Brandon R Porten) would like to highlight the following corrections to Table 2 in their review article, DOI: 10.1177/1358863X14534309. The review was printed in Vascular Medicine 2014; 19: 205–214. The authors would like to apologize for any...

  • clopidogrel.  // Royal Society of Medicine: Medicines;2002, p161 

    The article presents information on clopidogrel, an antiplatelet antithrombotic drug which is used to prevent thrombosis, but does not have an anticoagulant action. It works by stopping platelets sticking to one another or to the walls of blood vessels. It is used to reduce complications in...

  • Orgaran.  // Royal Society of Medicine: Medicines;2002, p413 

    The article presents information on Orgaran which is a proprietary, prescription-only preparation of the heparinoid, danaparoid sodium. It can be used as an anticoagulant for the prevention of deep vein thrombosis, and is available in a form for injection.

  • Management of Thrombotic and Cardiovascular Disorders in the New Millenium. Fareed, Jawed; Hoppensteadt, Debra A.; Bick, Rodger L. // Clinical & Applied Thrombosis/Hemostasis;Apr2003, Vol. 9 Issue 2, p101 

    Anticoagulants and antithrombotic drugs have played a key role in the prophylaxis, treatment and surgical/interventional management of thrombotic and cardiovascular disorders. There are several newer drugs which are currently developed for the anticoagulant management of cardiovascular diseases...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics